Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing The Long-Term Effectiveness and Safety of Mepolizumab 300mg/Month in the European Real-Life Setting (Mepo Long-term Study)

NCT07591753 is registered in ClinicalTrials.gov with European EGPA Study Group as lead sponsor.

NCT NCT07591753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07591753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing The Long-Term Effectiveness and Safety of Mepolizumab 300mg/Month in the European Real-Life Setting (Mepo Long-term Study)
Lead sponsor
European EGPA Study Group
Phase
Observational
Overall status
Completed
Start date
September 18, 2025
Completion date
March 31, 2026
Enrollment
591 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic granulomatosis with polyangiitis (churg-strauss) (egpa)